Quoin Pharmaceuticals has established a wholly-owned subsidiary in Japan to support the direct commercialization of QRX003, a potential treatment for Netherton Syndrome, following its Orphan Drug Designation by Japan’s Ministry of Health. This move strengthens Quoin's presence in one of its three core markets, alongside the US and Western Europe, where it plans to self-commercialize QRX003. The drug is currently in Phase 2 trials, with Phase 3 expected to start in late 2026 and potential approval filing in 2027. If approved, QRX003 could become the first approved treatment for this rare genetic skin disorder, improving patient care significantly.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
